Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Jan 10, 2024
Date Accepted: Sep 30, 2024
Date Submitted to PubMed: Oct 1, 2024
Facilitating Thought Progression Reduces Depressive Symptoms: A Randomized Controlled Trial
ABSTRACT
Background:
The constant rise and the prevalence of Major Depressive Disorder call for new, effective, and accessible interventions. Recent digital health developments suggest that dedicated online platforms may successfully address this gap
Objective:
We investigated the efficacy of a novel approach for treating depression by facilitating thought progression (FTP) through a gamified app.
Methods:
A randomized control trial was conducted, comparing the improvement in depression symptoms between participants who played with the app in the intervention group (n=74) and waitlist controls (n=27) over the course of eight weeks.
Results:
The results indicate that across multiple clinical measurements, app-playing participants showed greater and faster improvement in depressive symptoms compared with their waitlist control counterparts. Playing participants also showed high interest in continued post-trial engagement.
Conclusions:
These results demonstrate that the implementation of FTP-based interventions in future therapeutic contexts may prove fruitful in providing novel, accessible and effective treatment for depression. Clinical Trial: Clinical Trial Registry Name Clinicaltrials.gov (http://www.clinicaltrials.gov) Clinical Trial Registry URL https://clinicaltrials.gov/study/NCT05685758 Clinical Trial Registry Number NCT05685758
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.